ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 161 filers reported holding ARCUS BIOSCIENCES INC in Q1 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,805,000 | -11.6% | 379,100 | 0.0% | 0.01% | 0.0% |
| Q2 2023 | $7,700,000 | +11.4% | 379,100 | 0.0% | 0.01% | +12.5% |
| Q1 2023 | $6,915,000 | -11.8% | 379,100 | 0.0% | 0.01% | -11.1% |
| Q4 2022 | $7,840,000 | -21.1% | 379,100 | -0.2% | 0.01% | -25.0% |
| Q3 2022 | $9,937,000 | +3.2% | 379,858 | -0.0% | 0.01% | +9.1% |
| Q2 2022 | $9,626,000 | -19.7% | 379,880 | 0.0% | 0.01% | +22.2% |
| Q1 2022 | $11,989,000 | -22.0% | 379,880 | 0.0% | 0.01% | -30.8% |
| Q4 2021 | $15,374,000 | -4.6% | 379,880 | -17.8% | 0.01% | -7.1% |
| Q3 2021 | $16,109,000 | +26.6% | 461,980 | -0.3% | 0.01% | +40.0% |
| Q2 2021 | $12,725,000 | -2.2% | 463,398 | 0.0% | 0.01% | -44.4% |
| Q1 2021 | $13,012,000 | +8.4% | 463,398 | +0.2% | 0.02% | 0.0% |
| Q4 2020 | $12,003,000 | +51.5% | 462,364 | 0.0% | 0.02% | +38.5% |
| Q3 2020 | $7,925,000 | -20.2% | 462,364 | +15.3% | 0.01% | -23.5% |
| Q2 2020 | $9,925,000 | – | 401,164 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |